hotspot -WSS

hotspot

author：fashion 2025-09-29 23:28:13 - browse：51

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Google's generative AI to analyze medical images — and talk to docs

focus

WSS

Doctors are clamoring for more clarity on Paxlovid prescribing

Idaho college killings prosecutors challenge defense's grand jury claims

Doctors are clamoring for more clarity on Paxlovid prescribing

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Biden administration begins canceling student loan debt for 804,000 borrowers

How CRISPR works, explained in two minutes

Wikipedia

hotspot

leisure time

Hollywood unions extend contract negotiations for actors

Judge in Trump's classified documents case questions use of out

Alkermes shareholders re

Feed a cold, starve a fever? Here’s what science says

Walensky prepares to leave CDC — and Congress — behind

Health AI: on the border between health care and tech

Trump demands the U.S. pay no more for drugs than other countries … again

Election results set back Medicaid expansion plans

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Treatments for cramps don't cut it. Why aren't there better options?

hotspot

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Flash flood warnings continue for parts of Missouri, Illinois

Senators push IRS to launch nonprofit hospital probe

Be careful with at

Dozens dead from Maui wildfires: What we know about the victims

hotspot

focus

focus

Wikipedia